Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark

References

• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–6
   PubMed Web of Science ®Google Scholar
• Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation: The Rotterdam Study. Eur Heart J 2006;27:946-53
   Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections of future prevalence. Circulation 2006;114:119-25
   PubMed Web of Science ®Google Scholar
• Institute For Rational Pharmacotherapy. Behandling af atrieflimren. Rationel Pharmakoterapi Juni 2008 No 6
   Google Scholar
• The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-429
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501
   PubMed Web of Science ®Google Scholar
• Pengo V, Pegoraro C, Cucchini U, et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006;21:73-7
   PubMed Web of Science ®Google Scholar
• Ansell J, Hollowell J, Pengo V, et al. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis 2007;23:83-91
   PubMed Web of Science ®Google Scholar
• Amouyel P, Mismetti P, Langkilde LK, et al. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 2009;20:63-9
   PubMed Web of Science ®Google Scholar
• Friberg J, Gislason GH, Gadsbøll N, et al. Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation. J Intern Med 2006;259:173-8
   PubMedGoogle Scholar
• Palnum KH, Mehnert F, Andersen G, et al. Medical Prophylaxis following hospitalization for Ischemic Stroke: age- and sex-related differences and relation to mortality. Cerebrovasc Dis 2010;30:556-66
   PubMedGoogle Scholar
• Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-10
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. Am Heart J 2009;157:1064-73
   PubMed Web of Science ®Google Scholar
• Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105:908-19
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864-70
   PubMed Web of Science ®Google Scholar
• Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15
   PubMed Web of Science ®Google Scholar
• Statistics Denmark Table HISB8. Life table (2 years tables) by age, sex and life table (1981:1982-2009:2010). Copenhagen: Statistics Denmark. 2010 http://www.statistikbanken.dk. Accessed December 13, 2010
   Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al, on behalf of the RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 6736:61194-4
   Google Scholar
• Danish Medicines Agency. Medicinpriser. Copenhagen: Danish Medical Agency, 2011 http://www.medicinpriser.dk. Accessed March 15, 2011
   Google Scholar
• Danish Society of Cardiology. Antitrombotisk behandling ved kardiovaskulære sygdomme. Trombokardiologi. DCS Guidelines. Copenhagen: Danish Society of Cardiology, 2007
   Google Scholar
• Ministry of Health. Takstsystem 2011 – vejledning. Copenhagen: Ministry of Health, 2011
   Google Scholar
• Danish Medical Association. Honorartabel 01-04-2011. Copenhagen: Danish Medical Association, 2011
   Google Scholar
• Porsdal V, Boysen G. Direct costs during the first year after intracerebral hemorrhage. Eur J Neurol 1999;6:449-54
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Persson U, Glader EL, et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004;20:375-80
   PubMed Web of Science ®Google Scholar
• Statistics Denmark. Table PRIS8. Consumer price index, annual average (1900=100) by type (1900-2010). Copenhagen: Statistics Denmark, 2010 http://www.statistikbanken.dk. Accessed December 10, 2010
   Google Scholar
• Holm T, Lassen JF, Genefke J, et al. Cross-sectorial cooperation between general practice and hospital – shared care elucidated using anticoagulant therapy as an example. Medicinsk Teknologivurdering – puljeprojekter. Copenhagen: National Board of Health, 2006
   Google Scholar
• Hvelplund A, Galatius S, Madsen M, et al. Women with acute coronary syndrome are less invasively examined and subsequently less treated than men. Eur Heart J 2010;31:684-90
   PubMed Web of Science ®Google Scholar
• Committee on Health Promotion and Disease. Vi kan leve længere og sundere. Forebyggelseskommisionens anbefalinger til en styrket forbyggende indsats. Report. Copenhagen: Ministry of Health, Committee on Health Promotion and Disease Prevention, 2009
   Google Scholar
• National Board on Health. Referenceprogram for behandling af patienter med apopleksi. Copenhagen: National Board On Health, 2005
   Google Scholar
• Ghatnekar O, Glader EL. The effect of atrial fibrillation on stroke-related inpatient costs in Sweden: a 3-year analysis of registry incidence data from 2001. Value Health 2008;11:862-8
   PubMed Web of Science ®Google Scholar
• Brüggenjürgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health 2007;10:137-4
   PubMed Web of Science ®Google Scholar